cis-Diamminedichloroplatinum(II) Accumulation in Sensitive and Resistant Human Ovarian Carcinoma Cells

Cancer Research

Volumn 48, Issue 1, 1988, Pages 68-73

  Andrews, Paul A ^a   Velury, Sriharsha ^a   Mann, Stephen C ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; RADIOISOTOPE;

CELL CULTURE; CELL LINE; DRUG ACCUMULATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; OVARY CARCINOMA;

CARCINOMA; CELL MEMBRANE; CISPLATIN; DINITROPHENOLS; DRUG RESISTANCE; FEMALE; HUMAN; OUABAIN; OVARIAN NEOPLASMS; PLATINUM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0023875417     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Loehrer, P. J., and Einhorn, L. H. Cisplatin. Ann. Int. Med., 100:704-713, 1984.
2. Inoue, K., Mukaiyama, T., Mitsui, I., and Ogawa, M. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay. Cancer Chemother. Pharmacol., 15:208-213,1985.
3. Ozols, R. F., and Young, R. C. Chemotherapy of ovarian cancer. Semin. Oncol., 11:251-263,1984.
4. Hamilton, T. C., Winker, M. A., Louie, K. G., Batist, G., Behrens, B. C., Tsuruo, T., Grotzinger, K. R., McKoy, W. M., Young, R. C., and Ozols, R. F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol., 34: 2583-2586,1985.
5. Hromas, R. A., Andrews, P. A., Murphy, M. P., and Burns, C. P. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett, 34:9-13, 1987.
6. Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D., and Frei, E., III. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 47:388-393,1987.
7. Andrews, P. A., Murphy, M. P., and Howell, S. B. Differential potentiation of alkylating and platinating agent toxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res., 45:6250-6253,1985.
8. Andrews, P. A., Murphy, M. P., and Howell, S. B. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 19:149-154,1987.
9. Bakka, A., Endresen, L., Johnson, A. B. S., Edminson, P. D., and Rugstad, H. E. Resistance against cis-dichlorodiammineplatinum(II) in cultured cells with a high content of metallothionein. Toxicol. Appl. Pharmacol., 61:215-226.1981.
10. Behrens, B. C., Hamilton, Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47:414-418,1987.
11. Sheibani, N., and Eastman, A. A study of DNA repair in murine leukemia LI210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Proc. Am. Assoc. Cancer Res., 28:314,1987.
12. Kraker, A. J., and Moore, C. W. Characterization of reduced transport and DNA repair in Pt-resistant murine leukemia lines in vitro. Proc. Am. Assoc. Cancer Res., 28:317, 1987.
13. Pinto, A. L., and Lippard, S. J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta, 780: 167-180,1985.
14. Gale, G. R., Morris, C. R., Atkins, L. M., and Smith, A. B. Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res., 33:813-818,1973.
15. Davson, H. A Textbook of General Physiology, pp. 395–407. Baltimore, MD: Williams and Wilkins, 1970.
16. Christiansen, H. N. Biological transport. London: W. A. Benjamin, Inc., 1975.
17. Byfield, J. E., and Calabro-Jones, P. M. Carrier-dependent and independent transport of anti-cancer alkylating agents. Nature (Lond.), 294: 281–283, 1981.
18. Eicholtz-Wirth, H., and Hietal, B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br. J. Cancer., 54:239-243.1986.
19. Metcalfe, S. A., Cain, K., and Hill, B. T. Possible mechanism for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett., 31:163-169, 1986.
20. Canada, R. G. Terbium fluorescence studies of cisplatin binding to GH3/B6 pituitary tumor cells. Biochim. Biophys. Acta, 887:29-34,1986.
21. Williams, P. D., and Hottendorf, G. H. Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex. Cancer Treat. Rep., 69:875-880,1985.
22. Safirstein, R., Miller, P., and Guttenplan, J. B. Uptake and metabolism of cisplatin by rat kidney. Kidney Int., 25:753-758,1984.
23. Bird, J. E., Walser, M. M., and Quebbemann, A. J. Protective effect of organic cation transport inhibitors on cis-diamminedichloroplatinum-induced nephrotoxicity. J. Pharmacol. Exp. Ther., 231:752-758,1984.
24. Dornish, J. M., and Petersen, E. Protection from cis-dichlorodiammine-platinum-induced cell inactivation by aldehydes involves cell membrane amino groups. Cancer Lett., 29:235-243,1985.
25. Dornish, J. M., Melvik, J. E., and Peterson, E. O. Reduced cellular uptake of cis-dichlorodiammineplatinum by benzaldehyde. Anticancer Res., 6:583-588.1986.
26. Andrews, P. A., Kim, R. W., Murphy, M. P., and Howell, S. B. Altered cisplatin metabolism in cisplatin-resistant 2008 human ovarian carcinoma cells. Proc. Am. Assoc. Cancer Res., 27:270,1986.
27. Andrews, P. A., Murphy, M. P., and Howell, S. B. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Proc. Am. Assoc. Cancer Res., 27:289,1986.
28. Hromas, R. A., North, J. A., and Burns, C. P. Cisplatin uptake in L1210 leukemia cells resistant and sensitive to the drug. Proc. Am. Assoc. Cancer Res., 27:263,1986.
29. Richon, V. M., Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(U) in murine leukemia L1210 cells. Cancer Res., 47:2056-2061,1987.
30. Waud, W. R. Biochemical studies on resistance to cis-platinum (cis-DDP) in L1210 leukemia. Proc. Am. Assoc. Cancer Res., 27:262,1986.
31. Kraker, A. J., Steinkampf, R. W., and Moore, C. W. Transport of cis-Pt and cis-Pt analogs in sensitive and resistant murine leukemia cell lines. Proc. Am. Assoc. Cancer Res., 27:286,1986.
32. Wallner, K. E., DeGregorio, M. W., and Li, G. C. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res., 46:6242-6245,1986.
33. Hoeschele, J. D., Butler, T. A., Roberts, J. A., and Guyer, C. E. Analysis and refinement of the microscale synthesis of the 195Pt-labeled antitumor drug cis-dichlorodiammine-platinum(II), cis-DDP. Radiochim. Acta, 31:27-36,1982.
34. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem., 72:248-254,1976.
35. Kletzien, R. F., Pariza, M. W., Becker, J. E., and Potter, V. R. A method using 3-O-methyl-D-glucose and phloretin for the determination of intracellular water space of cells in monolayer culture. Anal. Biochem., 68: 537-544,1975.
36. Daley-Yates, P. T., and McBrien, D. C. H. Cisplatin metabolites: a method for their separation and for measurement of their renal clearance in vivo. Biochem. Pharmacol., 32:181-184,1983.
37. Hromas, R., Meyn, R., Jenkins, S., and Barlogie, B. Anguidine enhances cis-platinum-induced DNA crosslinks in Chinese hamster ovary cells. Proc. Am. Assoc. Cancer Res., 25:370, 1984.
38. Howell, S. B., Vick, J., and Andrews, P. A. Biochemical modulation of cisplatin by dipyridamole. Proc. Am. Assoc. Cancer Res., 28: 313,1987.
39. Guarino, A. M., Miller, D. S., Arnold, S. T., Pritchard, J. B., Davis, R. D., Urbanek, M. A., Miller, T. J., and Litterst, C. L. Platinate toxicity: past, present, and prospects. Cancer Treat. Rep., 63:1475-1483,1979.
40. Daley-Yates, P. T., and McBrien, D. C. H. The inhibition of renal ATPase by cisplatin and some biotransformation products. Chem. -Biol. Interact, 40:325-334, 1982.
41. Uomuzi, J., and Litterst, C. L. The effect of cisplatin on renal ATPase activity in vivo and in vitro. Cancer Chemother. Pharmacol., 15:93-96,1985.
42. Nechay, B. R., and Neldon, S. L. Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Rep., 68:1135-1141,1984.
43. Van den Berg, E. K., Jr., Brazy, P. C., Huang, A. T., and Dennis, V. W. Cisplatin-induced changes in sodium, chloride, and urea transport by the frog skin. Kidney Int, 19:8-14,1981.
44. Oakes, S. G., Santone, K. S., and Powis, G. Reversible inhibition of the calcium action potential in differentiated neuroblastoma cells by cis-plati-num(II)-diamminedichloride. Proc. Am. Assoc. Cancer Res., 27:266,1986.
45. Vassilev, P. M., Kanazirska, M. P., Charamella L. J. Dimitrov, N., and Tien, H. T. Changes in calcium channel activity in membranes from cis-diamminedichloroplatinum(II)-resistant and -sensitive L1210 cells. Cancer Res., 47:519-522,1987.
46. Scanlon, K. J., Safirstein, R. L., Thies, H., Gross, R. B., Waxman, S., and Guttenplan, J. B. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res., 43: 4211-4215,1983.
47. Shionaya, S., Lu, Y., and Scanlon, K. J. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloro-platinum(II). Cancer Res., 46:3445-3448,1986.
48. Gross, R. B., and Scanlon, K. J. Amino acid membrane transport properties of L1210 cells resistant to cisplatin. Chemotherapia, 5; 37-43,1986.
49. Aggarwal, S. K., and Niroomand-rad, I. Effect of cisplatin on the plasma membrane phosphatase activities in ascites sarcoma-180 cells. J. Histochem. Cytochem., 31:307-317,1983.
50. Tkacova, E., and Kuzela, S. Interaction of cis-diamminedichloroplatinum(II) with mitochondrial phosphate carrier. Neoplasma, 32:679-683, 1985.
51. Simpkins, H., and Pearlman, L. F. Interaction of two second generation platinum antitumor drugs with mouse thymocytes. Cancer Res., 46: 1433-1439,1986.
52. Sinha, B. K., and Chignell, C. F. Interaction of antitumor drugs with human erythrocyte ghost membranes and mastocytoma cells: a spin label study. Biochem. Biophys. Res. Commun., 86:1051-1057,1979.